Philip Chamberlain

Neomorph, Inc. is an American venture-backed biotechnology company that focuses on discovering innovative new medicines against 'undruggable' targets to solve critical problems in human health. The company is headquartered in an undisclosed location and has a key collaboration with the Center for Protein Degradation at the Dana Farber Cancer Institute. Neomorph's team is comprised of industry-leading experts in protein degradation and molecular glues who are committed to advancing the science and technology of molecular glue drug discovery. The company's patient-first, science-driven approach is complemented by its dedication to a supportive and collaborative work environment. Neomorph was founded by Eric Fischer, Philip Chamberlain, Scott A. Armstrong, and Benjamin Ebert, with Philip Chamberlain serving as the CEO since incorporation.

Neomorph, Inc. is an American venture-backed biotechnology company that focuses on discovering innovative new medicines against 'undruggable' targets to solve critical problems in human health. The company is headquartered in an undisclosed location and has a key collaboration with the Center for Protein Degradation at the Dana Farber Cancer Institute. Neomorph's team is comprised of industry-leading experts in protein degradation and molecular glues who are committed to advancing the science and technology of molecular glue drug discovery. The company's patient-first, science-driven approach is complemented by its dedication to a supportive and collaborative work environment. Neomorph was founded by Eric Fischer, Philip Chamberlain, Scott A. Armstrong, and Benjamin Ebert, with Philip Chamberlain serving as the CEO since incorporation.

Neomorph, Inc. is an American venture-backed biotechnology company that focuses on discovering innovative new medicines against 'undruggable' targets to solve critical problems in human health. The company is headquartered in an undisclosed location and has a key collaboration with the Center for Protein Degradation at the Dana Farber Cancer Institute. Neomorph's team is comprised of industry-leading experts in protein degradation and molecular glues who are committed to advancing the science and technology of molecular glue drug discovery. The company's patient-first, science-driven approach is complemented by its dedication to a supportive and collaborative work environment. Neomorph was founded by Eric Fischer, Philip Chamberlain, Scott A. Armstrong, and Benjamin Ebert, with Philip Chamberlain serving as the CEO since incorporation.

Neomorph, Inc. is an American venture-backed biotechnology company that focuses on discovering innovative new medicines against 'undruggable' targets to solve critical problems in human health. The company is headquartered in an undisclosed location and has a key collaboration with the Center for Protein Degradation at the Dana Farber Cancer Institute. Neomorph's team is comprised of industry-leading experts in protein degradation and molecular glues who are committed to advancing the science and technology of molecular glue drug discovery. The company's patient-first, science-driven approach is complemented by its dedication to a supportive and collaborative work environment. Neomorph was founded by Eric Fischer, Philip Chamberlain, Scott A. Armstrong, and Benjamin Ebert, with Philip Chamberlain serving as the CEO since incorporation.